로딩 중…
StockDiggingStockDigging

Teva Pharmaceutical Industries Limited

TEVA· NYSE
ILIL
$39.17+1.66%
2026-09-17

Financials

Valuation Metrics

Teva Pharmaceutical Industries Limited's Market Cap is $45.61B. At end of 2025 it was $35.86B. Ranked #339 of 3,121 in US market (top 11%), #245 of 1,658 on NYSE (top 15%), #19 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$45.61B
Revenue$17.31B
Net Income$706M
Total Assets$39.86B
Net Assets$7.76B
Employees32,008
Value
P/E64.60x
P/B5.88x
P/S2.63x
EV/EBITDA22.68x
FCF Yield2.96%
Profitability
ROE9.10%
ROA1.77%
Op. Margin11.45%
Revenue Growth4.13%
Financial Health
Debt Ratio413.77%
Total Debt$16.87B
FCF$1.35B
Cash$3.65B
Current Ratio0.88x
Net Debt/EBITDA5.10x
Performance
1Y Return113.11%
1M Return7.08%
From 52W High-1.33%
1Y MDD-21.79%
Trading
Volume4,665,764 shares
Trading Value$183M
Per Share
EPS$0.61
BPS$6.66

Company Info

CEO Richard D. Francis
Employees 32,008
HQ Tel Aviv, IL

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.